Poor
Mostly Not Aligned
Patient Risk:
Moderate
Summary
Many mechanistic and clinical-efficacy/trial-design claims are not supported by the provided label excerpts. Only limited safety statements (fatigue, nausea, diarrhea) and partial identity naming (PM1183) are supported.
Category Scores
Accurate Statements
Lurbinectedin is a chemotherapeutic agent.
11 DESCRIPTION states ZEPZELCA (lurbinectedin) is an alkylating drug.
Lurbinectedin is also known as PM1183.
6.1 Clinical Trials Experience includes Study B-005 referenced as “PM1183-B-005-14”.
Lurbinectedin can cause side effects such as fatigue.
6.1 Clinical Trials Experience lists fatigue as a most common adverse reaction (≥20% pooled safety; and Table 5 includes fatigue in Study B-005).
Lurbinectedin can cause side effects such as nausea.
6.1 Clinical Trials Experience lists nausea as a most common adverse reaction (≥20% pooled safety; and Table 5 includes nausea in Study B-005).
Lurbinectedin can cause side effects such as diarrhea.
6.1 Clinical Trials Experience: pooled safety for advanced solid tumors lists diarrhea; Table 5 in Study B-005 includes diarrhea.
Unsupported Statements
Lurbinectedin is a synthetic derivative of the natural product PM02734.
Not supported by the provided label sections.
Lurbinectedin is a small molecule inhibitor.
Not supported by the provided label sections.
Lurbinectedin targets the transcriptional machinery of cancer cells.
Mechanism described in 12.1 is DNA alkylation/adduct formation and downstream effects; transcriptional machinery targeting as stated is not supported by the provided excerpts.
Lurbinectedin binds to RNA polymerase II.
RNA polymerase II binding is not stated in the provided label excerpts.
By binding to RNA polymerase II, lurbinectedin disrupts the expression of genes involved in cell proliferation.
Depends on unsupported RNA polymerase II binding.
By binding to RNA polymerase II, lurbinectedin disrupts the expression of genes involved in cell survival.
Depends on unsupported RNA polymerase II binding.
By binding to RNA polymerase II, lurbinectedin disrupts the expression of genes involved in angiogenesis.
Depends on unsupported RNA polymerase II binding.
Lurbinectedin leads to decreased expression of genes involved in cell proliferation and survival.
Not supported by the provided label excerpts.
Lurbinectedin induces apoptosis in cancer cells.
Apoptosis induction is not stated in the provided label excerpts.
Lurbinectedin inhibits expression of genes involved in angiogenesis.
Not supported by the provided label excerpts.
Lurbinectedin has been investigated in clinical trials for efficacy and safety in patients with various types of cancer.
Not directly supported as stated; label excerpt provided only supports safety evaluation and includes advanced solid tumors, but does not support the specific breadth/efficacy wording in the claim.
A phase I clinical trial in relapsed or refractory small cell lung cancer (SCLC) found lurbinectedin was well-tolerated.
Phase and trial design/activity (phase I; relapsed/refractory SCLC) are not stated in the provided label excerpts.
A phase I clinical trial in relapsed or refractory small cell lung cancer (SCLC) found lurbinectedin showed promising antitumor activity.
Phase and efficacy/antitumor activity wording are not supported by the provided label excerpts.
A phase II clinical trial found lurbinectedin improved overall survival in patients with SCLC.
Provided label excerpts do not include phase II overall survival results.
In a study of patients with SCLC who received lurbinectedin, median overall survival was 8.2 months.
Overall survival numerical results are not present in the provided label excerpts.
In a study of patients with SCLC, the control group median overall survival was 4.3 months.
Control group survival comparator and numerical results are not present in the provided label excerpts.
In patients with SCLC, lurbinectedin improved progression-free survival.
Progression-free survival is not present in the provided label excerpts.
In patients with SCLC, lurbinectedin improved overall survival.
Overall survival improvement is not present in the provided label excerpts (only safety information is provided).
Development of resistance to lurbinectedin can limit its effectiveness.
Resistance is not stated in the provided label excerpts.
According to DrugPatentWatch.com, lurbinectedin is under patent protection until 2034.
Not supported by the provided FDA label excerpts (and is an external source claim).
Contradictions
Important Omissions
No statements in the provided claims address FDA label items related to boxed warnings, contraindications, dosing/administration instructions, drug interactions, or monitoring. Material label safety requirements may therefore be unassessed.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several claims assert mechanism and efficacy findings not supported by the provided label excerpts; while they do not directly provide dosing or contraindication instructions, unsupported efficacy/mechanism statements could mislead on expected effects. Safety-related symptom claims (fatigue/nausea/diarrhea) are supported.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Mostly Not Aligned
Primary Issue
Large portion of claims (mechanism involving RNA polymerase II, gene-expression effects, apoptosis, resistance, and multiple phase/efficacy survival endpoints) are not supported by the provided FDA label excerpts.
Suggested Improvement
Restrict assertions to text present in the provided label sections (e.g., label-supported alkylating-DNA adduct mechanism and listed common adverse reactions). Remove or rephrase unsupported claims (especially RNA polymerase II binding and numerical survival/PFS results) unless corresponding label text is provided.